The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

Trump has so far not targeted any of Biden's signature healthcare policies, including Medicare drug pricing negotiation powers, the $35 monthly cap on insulin copays, and the $2,000 annual cap on out-of-pocket spending on prescription drug costs.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

One of those now-cancelled policies directed Medicare to investigate ways to slash drug costs, including the possibility of a $2 monthly out-of-pocket cap on some generic medications. Monday's actions also follow through on a key goal of Trump's first term -- weakening Obamacare.

Trump reversed former President Joe Biden's order on "Lowering Prescription Drug Costs for Americans" on Monday.